Volatile Anesthetic Regulation of TASK Tandem Pore Potassium Channels
TASK 串联孔钾通道的挥发性麻醉调节
基本信息
- 批准号:7530533
- 负责人:
- 金额:$ 13.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAgonistAmino Acid SequenceAnesthesia Department, HospitalAnesthesia proceduresAnestheticsBreathingBronchodilationCellsChemosensitizationClinicalConsciousCoupledDepressed moodDevelopmentElectrodesElectrophysiology (science)ExhibitsFacultyGeneral AnesthesiaGeneral HospitalsGeneral anesthetic drugsHalothaneHypoxiaInbred F344 RatsIon ChannelIsofluraneKnowledgeLeadMammalian CellMediatingMemoryMethodsMolecularMolecular Biology TechniquesMuscarinicsMuscle TonusNervous system structureNeuraxisNeurosciencesPeripheralPharmaceutical PreparationsPharmacologyPotassiumPotassium ChannelPrincipal InvestigatorProgram DevelopmentProteinsPublic HealthRNA InterferenceReceptor ActivationReceptor InhibitionRegulationResearchResearch PersonnelResistanceRoleSignaling ProteinSiteSite-Directed MutagenesisTestingThyroid GlandTissuesTraining ProgramsVasodilationWakefulnessWorkXenopus oocytebasecell typeclinically relevantdesfluranemedical schoolsmembermutantnovelpatch clampprogramsreceptor couplingreceptor functionreconstitutionresponsesevofluraneskillsvoltage clamp
项目摘要
DESCRIPTION (provided by applicant): This proposal describes a 5-year training program for the development of an independent investigator in volatile anesthetic mechanisms. The principal investigator is a faculty member in the Department of Anesthesia, Harvard Medical School, with a background in electrophysiology, who will acquire new knowledge and skills in neuroscience and pharmacology sufficient to lead his own independent research program. Work will be conducted in the Mallinckrodt Pharmacology Research Unit at Massachussets General Hospital which focuses on volatile anesthetic mechanisms. Our SPECIFIC AIMS wil test the novel hypothesis that volatile anesthetics potentiate TASK-3 function indirectly by inhibition of basal or agonst-mediated Galpha-q protein coupled receptor (GqPCR) activity. The TASK-3 tandem pore potassium channel is a volatile anesthetic-potentiated and pH- and hypoxia-inhibited ion channel. TASK-3 is widely expressed in the central nervous system and in peripheral tissue and has a role in chemosensing in a variety of cell types, including those involved in regulation of breathing. TASK-3 function is also inhibited by GqPCR activation. GqPCRs in the CNS regulate memory, wakefulness, and consciousness and peripherally are important regulators of smooth muscle tone. The function of many GqPCRs are inhibited by volatile anesthetics. To test our hypothesis we will use two-electrode voltage clamp of Xenopus oocytes or Ussing Chamber studies of Fischer Rat Thyroid cells heterologously expressing TASK-3 channels and ml or m3 GqPCRs and Galpha-q protein. We will also employ the excised patch-clamp method, and several molecular biology techniques including RNA interference and site-directed mutagenesis. LONG TERM GOALS: This project will clairfy the molecular mechanism by which volatile anesthetics potentiate TASK channels. PUBLIC HEALTH RELEVANCE This work will help establish principles to guide development of safer anesthetic drugs that do not effect breathing and further elucidate the mechanism by which these drugs induce anesthesia.
描述(由申请人提供):本提案描述了一项为期5年的培训计划,旨在培养一名挥发性麻醉机制方面的独立研究者。首席研究员是哈佛医学院麻醉系的一名教员,具有电生理学背景,他将获得神经科学和药理学方面的新知识和技能,足以领导他自己的独立研究项目。工作将在马萨诸塞州总医院的Mallinckrodt药理学研究单位进行,重点是挥发性麻醉机制。我们的SPECIFIC AIMS将测试挥发性麻醉剂通过抑制基础或激动剂介导的galphaq蛋白偶联受体(GqPCR)活性间接增强TASK-3功能的新假设。TASK-3串联孔钾通道是一种挥发性麻醉增强、pH和缺氧抑制的离子通道。TASK-3在中枢神经系统和外周组织中广泛表达,并在多种细胞类型的化学感应中发挥作用,包括那些参与呼吸调节的细胞。TASK-3功能也被GqPCR激活所抑制。中枢神经系统中的gqpcr调节记忆、觉醒和意识,并在周围是平滑肌张力的重要调节因子。许多gqpcr的功能被挥发性麻醉剂抑制。为了验证我们的假设,我们将使用爪蟾卵母细胞的双电极电压钳或Fischer大鼠甲状腺细胞异种表达TASK-3通道和ml或m3 gqpcr和galphaq蛋白的使用室研究。我们还将采用切除膜片钳方法,以及一些分子生物学技术,包括RNA干扰和定点诱变。长期目标:该项目将阐明挥发性麻醉剂增强TASK通道的分子机制。这项工作将有助于建立指导开发不影响呼吸的更安全麻醉药物的原则,并进一步阐明这些药物诱导麻醉的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph F Cotten其他文献
Joseph F Cotten的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph F Cotten', 18)}}的其他基金
Anesthetic activation of TASK-3 tandem pore potassium channels: molecular mechanisms and behavioral effects
TASK-3串联孔钾通道的麻醉激活:分子机制和行为效应
- 批准号:
9900029 - 财政年份:2018
- 资助金额:
$ 13.09万 - 项目类别:
TASK Potassium Channel Antagonists to Treat Opioid Depression of Breathing
TASK 钾通道拮抗剂治疗阿片类药物呼吸抑制
- 批准号:
9264573 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
TASK Potassium Channel Antagonists to Treat Opioid Depression of Breathing
TASK 钾通道拮抗剂治疗阿片类药物呼吸抑制
- 批准号:
8843947 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
TASK Potassium Channel Antagonists to Treat Opioid Depression of Breathing
TASK 钾通道拮抗剂治疗阿片类药物呼吸抑制
- 批准号:
9058592 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
TASK Potassium Channel Antagonists to Treat Opioid Depression of Breathing
TASK 钾通道拮抗剂治疗阿片类药物呼吸抑制
- 批准号:
8478315 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
TASK Potassium Channel Antagonists to Treat Opioid Depression of Breathing
TASK 钾通道拮抗剂治疗阿片类药物呼吸抑制
- 批准号:
8665480 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
Volatile Anesthetic Regulation of TASK Tandem Pore Potassium Channels
TASK 串联孔钾通道的挥发性麻醉调节
- 批准号:
7922796 - 财政年份:2009
- 资助金额:
$ 13.09万 - 项目类别:
Volatile Anesthetic Regulation of TASK Tandem Pore Potassium Channels
TASK 串联孔钾通道的挥发性麻醉调节
- 批准号:
7681262 - 财政年份:2008
- 资助金额:
$ 13.09万 - 项目类别:
Volatile Anesthetic Regulation of TASK Tandem Pore Potassium Channels
TASK 串联孔钾通道的挥发性麻醉调节
- 批准号:
7924160 - 财政年份:2008
- 资助金额:
$ 13.09万 - 项目类别:
Volatile Anesthetic Regulation of TASK Tandem Pore Potassium Channels
TASK 串联孔钾通道的挥发性麻醉调节
- 批准号:
8320182 - 财政年份:2008
- 资助金额:
$ 13.09万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 13.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 13.09万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:














{{item.name}}会员




